Global & Domestic Market Update – 16 June 2025
Markets on 16th June 2025 showed a defensive tone following increased global uncertainties and some surprise corporate actions.
Global Indicators & Commodities
- Crude Oil: Went up to $73.46/barrel in the wake of geopolitical tensions in the Middle East.
- INR: Rupee dipped, with USD/INR around ₹86.05.
- US Dollar Index: Stayed at 97.69.
- US 10-Year Bond Yield: At 4.42%, reflecting investor wariness.
- VIX: Market fear index stayed close to 14.82.
- Gold & Silver: Both remained safe haven at ₹99,900 and ₹1,06,500 respectively.
- Base Metals: Zinc and Copper continued to stay bullish on expectation of industrial demand.
Crypto Meets Retail: Walmart & Amazon To Issue Stablecoins
Two retailing giants, Walmart and Amazon, are said to be preparing to introduce their own stablecoins—a step that can transform digital payments as well as e-commerce websites worldwide.
Geopolitical Tensions: Ripple Across Industries
- Escalating tensions between Iran and Israel are bound to impact a number of Indian and international companies:
- Adani Ports owing to its Israeli Haifa Port holding.
- Sun Pharma, Teva Pharma, Taro Pharma, DR Reddy’s, and Lupin with pharma businesses in Israel.
- TCS, Infosys, Wipro, Tech Mahindra, SBI, L&T, Titan, Kalyan Jewellers, NMDC will also experience supply chain or business disruption due to business links.
- Basmati rice, soya milk, and tea export-oriented industries could be impacted.
India’s Macro & Institutional Flow
- Wholesale Price Index (WPI): Increased to 0.39%, showing sluggish inflation revival.
- FII/DII Activity
- FII: Net sellers of ₹1,263 crore.
- DII: Net buyers with ₹3,041 crore inflows.
Corporate Headlines
Tata Motors & JLR Outlook
- JLR anticipates zero positive free cash flow in FY26.
- EBIT margin guidance: 5% to 6%.
- The company reasserts long-term growth strategy.
Pharma Sector Updates
- Lupin & Sino Universal Pharma to launch TIOTROPIUM inhaler in China.
- Sun Pharma’s Halol plant receives Form 483 by USFDA after inspection.
- Natco Pharma’s API business also released Form 483 after USFDA audit.
- Sinjin receives clean chit (EIR + VAI) by USFDA for Bangalore unit.
Infrastructure, Cement & Realty
- Birla Corp is the winner of Rajasthan limestone mine auction.
- NTPC new unit increases capacity to 61,368 MW; to raise ₹4,000 crore via NCDs.
- Omaxe to invest ₹1,000 crore in Amritsar Township.
- ARAKADE Developers wins ₹2,000 crore Thane Metro contract.
✈️ Transport & Logistics
SpiceJet reports 12x profit growth, surprising the street.
Investments, Ratings & Deals
- ITC buys Seresta Natural Bioproducts in a ₹400 crore transaction.
- Upgrades Yes Bank rating by Moody’s to Ba3 (Stable).
- Upgrades Jaguar (Tata Motors) rating to Ba1 (Positive).
- AUTHUM buys One Source Speciality shares of Debicom Capital.
- Capri Global completes QIP allotment of ₹2,000 crore.
- UltraTech Cement sells 7% stake in India Cement.
⚙️ Tech & Innovation
- TCS inks historic IT contract with Denmark’s SALLING Group for AI-powered cloud migration.
- Sterlite Technologies initiates AI-powered data center solution.
- AlphaGrape receives SEBI clearance to introduce mutual funds.
Stock Market Sectoral Trends
Good buying was observed in:
- Midcap
- Smallcap
- IT
- Realty
- Metals
- Oil & Gas
- Public Sector Enterprises (PSEs)
- Banks
Conclusion
Markets were opportunistic yet prudent on 16 June 2025. To the extent that global tensions threw a long shadow, India’s domestic inflows, corporate resilience, and economic resilience created a rosy picture for investors.
Disclaimer
Barawakar does not provide financial advice and the information on the website www.Barawakar.com is only for general use. Users of Barawakar accept full responsibility in the possibility of losing capital. Barawakar strives to provide correct information, but offers no guarantees regarding the accuracy or completeness of data given.
In case of any investments planning, make sure to seek professional counsel or do amplify your own research. The www.barawakar.com website is available to users without warranties on availability or functionality. By using this website, you accept the terms of these conditions.
For any questions, feel free to reach out to us.